Currently Viewing:
American Diabetes Association (ADA) 2017
Dr Alan Carter on Biosimilars in the Insulin Market
July 27, 2017
Dr Eda Cengiz on New Technologies in Diabetes Management
July 26, 2017
Robby Booth of Glytec Discusses the Importance of Data-Sharing Capabilities
July 24, 2017
Dr Andrew Rhinehart: Improving Intermediate Outcomes in Diabetes Research
July 20, 2017
WellDoc Data Offer Promise for Integrating Diabetes Data Into Workflow
July 17, 2017
Dr Alan Carter on the Steps to Managing Rising Insulin Costs
July 17, 2017
Dr Eda Cengiz Discusses the Future of Diabetes Management
July 13, 2017
Nina Brown-Ashford: DPP Will Improve Care and Costs for Prediabetes Patients
July 06, 2017
Dr Alan Carter on Increasing Insulin Costs
July 04, 2017
Dr William Polonsky on Diabetes Patients' Treatment Satisfaction and Insulin Adherence
June 29, 2017
Dr Eda Cengiz on Improvements in Closed-Loop Systems
June 26, 2017
With Glytec, Hospital Moves to Basal-Bolus Insulin, Saves $9.7 Million
June 21, 2017
Raymie McFarland Discusses Findings From Glytec's Basal-Bolus Insulin Study
June 21, 2017
Sanofi Presents New Results for Insulin GLP-1 Combo Soliqua
June 13, 2017
Dr Bruce Neal Discusses Canagliflozin's Potential for Heart Failure Prevention
June 13, 2017
Currently Reading
Dr Eda Cengiz Explains Artificial Pancreas Systems' Implications for Patients and Clinicians
June 13, 2017
CANVAS Finds Lower Risk of CV Events for Invokana
June 12, 2017
Phase 3 Results Show Lower A1C for Ertugliflozin, Combined With Metformin and With Sitagliptin
June 12, 2017
Heart Failure Needs More Attention in Diabetes Drug Trials, Expert Says
June 11, 2017

Dr Eda Cengiz Explains Artificial Pancreas Systems' Implications for Patients and Clinicians

Hybrid closed-loop insulin delivery systems, also referred to as an artificial pancreas, can help improve the management of diabetes while researchers seek a cure, as well as provide reassurance for patients and their families, according to Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine.


Hybrid closed-loop insulin delivery systems, also referred to as an artificial pancreas, can help improve the management of diabetes while researchers seek a cure, as well as provide reassurance for patients and their families, according to Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine.

Transcript (slightly modified)

The FDA approved the MiniMed 670G closed loop system in September 2016. What are the implications of this approval for patients and physicians?

Diabetes is not an easy disease, and it keeps you busy with blood sugar checks. You have to think about carbohydrate counting, you have to check your blood sugar patterns. The whole idea about this system is we’re trying to give people a break and let the system do some of the work so they don’t have to think about diabetes as much and they can enjoy their lives. For people with diabetes, I think this is going to be an amazing opportunity to utilize technology to take away some of the burden of diabetes management.

Another major advantage is while it’s taking away some of the burden, it’s also a safe system. At night, the blood sugar control is outstanding. None of the clinicians, I’m a clinician myself, we’re not that good. We cannot adjust insulin dose every night for each patient and optimize it in a way that they will have blood sugars throughout the night. A lot of people worry about low blood sugars in the middle of the night, but if you have a system adjusting insulin and checking glucose patterns every 5 minutes, that’s amazing. That’s how you can achieve almost perfect control overnight and you don’t have to worry about it, you can sleep through the night.

I’m a pediatric endocrinologist, so for my patient group, their parents can sleep at night. Our kiddos can go to sleepovers; they don’t have to worry about what’s going to happen with blood sugars. Their parents can actually check the system, see what’s going on, and on top of that now they have a little bit of freedom to actually do whatever they want because the system will alert them if the predicted blood sugar is going to be low at a certain time point.

Those are all benefits of it for people with diabetes. As a clinician, 70% to 80% of our patients are not within target range, and despite everything we try, we cannot even reach a 50% or a 30% improvement. But with these systems, there’s a great opportunity. If you have 70% or 80% of your patients in poor glycemic control, that translates into future complications.

While we’re trying to discover the cure for diabetes, we can’t afford to wait for a cure. In the meantime, we have to keep our patients happy, healthy, and from a clinician perspective I think artificial pancreas hybrid closed-loop systems can achieve better glycemic control and also reduce complications of future diabetes if we can keep improving blood sugar control. Our patients will be healthy until we discover the cure for diabetes, so we’re hoping that those are going to be some outcomes of hybrid closed-loop once it’s implemented widely in the clinical field.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!